Drug intelligence / Profile preview

BI 860585 + paclitaxel

Development stage: Unknown
Lead developer: Xynomic Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

**BI 860585 + paclitaxel** is a combination of BI 860585, a potent, selective, ATP-competitive inhibitor targeting mammalian target of rapamycin complex 1 and 2 (**mTORC1/2**), and paclitaxel, a microtubule-stabilizing antineoplastic agent. BI 860585 inhibits mTOR serine/threonine kinase activity, blocking cancer cell growth and survival signaling pathways; paclitaxel promotes microtubule assembly and inhibits disassembly, leading to cell cycle arrest and apoptosis. The combination has been studied in phase 1 for advanced/metastatic solid tumors to assess safety, pharmacokinetics, and anti-tumor efficacy.

Targets

TUBB (Tubulin (alpha and beta subunits))Mechanistic target of rapamycin kinase complex 2Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on BI 860585 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 860585 + paclitaxel.

Explore the full profile